|
1
|
Bauersachs R, Zeymer U, Brière JB, Marre
C, Bowrin K and Huelsebeck M: Burden of coronary artery disease and
peripheral artery disease: A literature review. Cardiovasc Ther.
2019(8295054)2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Tripolt NJ, Kolesnik E, Pferschy PN,
Verheyen N, Ablasser K, Sailer S, Alber H, Berger R, Kaulfersch C,
Leitner K, et al: Impact of EMpagliflozin on cardiac function and
biomarkers of heart failure in patients with acute MYocardial
infarction-the EMMY trial. Am Heart J. 221:39–47. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Fontes-Carvalho R, Azevedo AI, Sampaio F,
Teixeira M, Bettencourt N, Campos L, Gonçalves FR, Ribeiro VG,
Azevedo A and Leite-Moreira A: The effect of exercise training on
diastolic and systolic function after acute myocardial infarction:
A randomized study. Medicine (Baltimore). 94(e1450)2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Miyazaki S, Kasai T, Miyauchi K, Miyazaki
T, Akimoto Y, Takagi A, Aihara K, Kawamura M, Suwa S, Kojima S, et
al: Changes of matrix metalloproteinase-9 level is associated with
left ventricular remodeling following acute myocardial infarction
among patients treated with trandolapril, valsartan or both. Circ
J. 74:1158–1164. 2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Her AY, Choi BG, Rha SW, Kim YH, Choi CU
and Jeong MH: The impact of angiotensin-converting-enzyme
inhibitors versus angiotensin receptor blockers on 3-year clinical
outcomes in patients with acute myocardial infarction without
hypertension. PLoS One. 15(e0242314)2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
McMurray JJ, Packer M, Desai AS, Gong J,
Lefkowitz M, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg
K, et al: Baseline characteristics and treatment of patients in
prospective comparison of ARNI with ACEI to determine impact on
global mortality and morbidity in heart failure trial
(PARADIGM-HF). Eur J Heart Fail. 16:817–825. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
7
|
Sauer AJ, Cole R, Jensen BC, Pal J, Sharma
N, Yehya A and Vader J: Practical guidance on the use of
sacubitril/valsartan for heart failure. Heart Fail Rev. 24:167–176.
2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Khder Y, Shi V, McMurray JJV and Lefkowitz
MP: Sacubitril/valsartan (LCZ696) in heart failure. Handb Exp
Pharmacol. 243:133–165. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Singh JSS, Burrell LM, Cherif M, Squire
IB, Clark AL and Lang CC: Sacubitril/valsartan: Beyond natriuretic
peptides. Heart. 103:1569–1577. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Böhm M, Young R, Jhund PS, Solomon SD,
Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K,
et al: Systolic blood pressure, cardiovascular outcomes and
efficacy and safety of sacubitril/valsartan (LCZ696) in patients
with chronic heart failure and reduced ejection fraction: Results
from PARADIGM-HF. Eur Heart J. 38:1132–1143. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kang H, Zhang J, Zhang X, Qin G, Wang K,
Deng Z, Fang Y and Chen G: Effects of sacubitril/valsartan in
patients with heart failure and chronic kidney disease: A
meta-analysis. Eur J Pharmacol. 884(173444)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Methley AM, Campbell S, Chew-Graham C,
McNally R and Cheraghi-Sohi S: PICO, PICOS and SPIDER: A comparison
study of specificity and sensitivity in three search tools for
qualitative systematic reviews. BMC Health Serv Res.
14(579)2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zeng X, Zhang Y, Kwong JS, Zhang C, Li S,
Sun F, Niu Y and Du L: The methodological quality assessment tools
for preclinical and clinical studies, systematic review and
meta-analysis, and clinical practice guideline: A systematic
review. J Evid Based Med. 8:2–10. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zhang Y, Wu Y, Zhang K, Ke Z, Hu P and Jin
D: Benefits of early administration of Sacubitril/Valsartan in
patients with ST-elevation myocardial infarction after primary
percutaneous coronary intervention. Coron Artery Dis. 32:427–431.
2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wang H and Fu X: Effects of
sacubitril/valsartan on ventricular remodeling in patents with left
ventricular systolic dysfunction following acute anterior wall
myocardial infarction. Coron Artery Dis. 32:418–426.
2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Rezq A, Saad M and El Nozahi M: Comparison
of the efficacy and safety of sacubitril/valsartan versus ramipril
in patients with ST-segment elevation myocardial infarction. Am J
Cardiol. 143:7–13. 2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Docherty KF, Campbell RT, Brooksbank KJM,
Dreisbach JG, Forsyth P, Godeseth RL, Hopkins T, Jackson AM, Lee
MMY, McConnachie A, et al: Effect of neprilysin inhibition on left
ventricular remodeling in patients with asymptomatic left
ventricular systolic dysfunction late after myocardial infarction.
Circulation. 144:199–209. 2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Sawhney JP: Angiotensine converting enzyme
inhibitors in acute myocardial infarction-a review. Indian Heart J.
63:71–78. 2011.PubMed/NCBI
|
|
19
|
Ibanez B, James S, Agewall S, Antunes MJ,
Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA,
Halvorsen S, et al: 2017 ESC guidelines for the management of acute
myocardial infarction in patients presenting with ST-segment
elevation: The task force for the management of acute myocardial
infarction in patients presenting with ST-segment elevation of the
European society of cardiology (ESC). Eur Heart J. 39:119–177.
2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Cespón-Fernández M, Raposeiras-Roubín S,
Abu-Assi E, Manzano-Fernández S, Flores-Blanco P, Barreiro-Pardal
C, Castiñeira-Busto M, Muñoz-Pousa I, López-Rodríguez E,
Caneiro-Queija B, et al: Renin-angiotensin system blockade and risk
of heart failure after myocardial infarction based on left
ventricular ejection fraction: A retrospective cohort study. Am J
Cardiovasc Drugs. 19:487–495. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Nguyen E, Weeda ER and White CM: A review
of new pharmacologic treatments for patients with chronic heart
failure with reduced ejection fraction. J Clin Pharmacol.
56:936–947. 2016.PubMed/NCBI View
Article : Google Scholar
|
|
22
|
Ponikowski P, Voors AA, Anker SD, Bueno H,
Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP,
Jankowska EA, et al: 2016 ESC guidelines for the diagnosis and
treatment of acute and chronic heart failure: The task force for
the diagnosis and treatment of acute and chronic heart failure of
the European society of cardiology (ESC). Developed with the
special contribution of the heart failure association (HFA) of the
ESC. Eur J Heart Fail. 18:891–975. 2016.PubMed/NCBI View
Article : Google Scholar
|
|
23
|
Yancy CW, Jessup M, Bozkurt B, Butler J,
Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi
JL, et al: 2013 ACCF/AHA guideline for the management of heart
failure: A report of the American college of cardiology
foundation/American heart association task force on practice
guidelines. J Am Coll Cardiol. 62:e147–e239. 2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ferrari R, Cardoso J, Fonseca MC, Aguiar
C, Moreira JI, Fucili A and Rapezzi C: ‘Italian-Portuguese Action
on Heart Failure’ Group. ARNIs: Balancing ‘the good and the bad’ of
neuroendocrine response to HF. Clin Res Cardiol. 109:599–610.
2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ardiana F and Suciati and Indrayanto G:
Valsartan. Profiles Drug Subst Excip Relat Methodol. 40:431–493.
2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Drugs and Lactation Database (LactMed)
[Internet]. Bethesda (MD): National Library of Medicine (US);
2006-. Sacubitril, 2019.
|
|
27
|
Zhao J, Zeng Y and Shen X: Efficacy and
safety of early initiation of sacubitril/valsartan in patients
after acute myocardial infarction: A meta-analysis. Clin Cardiol.
44:1354–1359. 2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Tsutsui H, Momomura S, Saito Y, Ito H,
Yamamoto K, Ohishi T, Okino N and Guo W: Efficacy and safety of
sacubitril/valsartan (LCZ696) in Japanese patients with chronic
heart failure and reduced ejection fraction: Rationale for and
design of the randomized, double-blind PARALLEL-HF study. J
Cardiol. 70:225–231. 2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Jering KS, Claggett B, Pfeffer MA, Granger
C, Køber L, Lewis EF, Maggioni AP, Mann D, McMurray JJV, Rouleau
JL, et al: Prospective ARNI vs ACE inhibitor trial to determine
superiority in reducing heart failure events after myocardial
infarction (PARADISE-MI): Design and baseline characteristics. Eur
J Heart Fail. 23:1040–1048. 2021.PubMed/NCBI View Article : Google Scholar
|
